Karyopharm Therapeutics Inc. (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $10.39, for a total value of $103,900.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Karyopharm Therapeutics Inc. (NASDAQ KPTI) traded up $0.48 during midday trading on Monday, hitting $11.11. The stock had a trading volume of 204,500 shares, compared to its average volume of 234,501. Karyopharm Therapeutics Inc. has a fifty-two week low of $7.48 and a fifty-two week high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. sell-side analysts anticipate that Karyopharm Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.
Several analysts have commented on the company. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. assumed coverage on Karyopharm Therapeutics in a report on Wednesday, November 15th. They issued a “buy” rating and a $23.00 price target for the company. Royal Bank Of Canada assumed coverage on Karyopharm Therapeutics in a report on Thursday, September 14th. They issued an “outperform” rating and a $14.00 price target for the company. Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, November 15th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.33.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
What are top analysts saying about Karyopharm Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Karyopharm Therapeutics Inc. and related companies.